SCHEMBL6183813

SCHEMBL6183813

CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4)ncn3[C@@H]3CCNC3)cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 0.58
MAPK13 O15264 3/20 0.51
MAPK12 P53778 3/20 0.51
MAPK11 Q15759 3/20 0.51
PRKD3 O94806 2/20 0.44
MAP4K4 O95819 2/20 0.44
PRKACA P17612 2/20 0.44
CSNK1A1 P48729 2/20 0.44
CSNK1D P48730 2/20 0.44
MINK1 Q8N4C8 2/20 0.44
MAP4K5 Q9Y4K4 2/20 0.44
HSPB1 P04792 1/20 0.44
PRKCB P05771 1/20 0.44
PRKCA P17252 1/20 0.44
RIPK2 O43353 1/20 0.44
DYRK3 O43781 1/20 0.44
PRKCG P05129 1/20 0.44
LCK P06239 1/20 0.44
LYN P07948 1/20 0.44
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183811 1.00 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6182792 1.00 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL4833479 0.74 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL5777214 0.73 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL1639238 0.72 MAPK14 (0.65) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL5771936 0.72 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6182328 0.70 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL4915290 0.70 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL5772546 0.69 MAPK14 (0.90) MAPK14CSNK1DPIM1MAPK1FLT4
Vk-19911 SCHEMBL140202 0.68 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1247810-B1 Novel benzotriazoles anti-inflammatory compounds PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6664395-B2 Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia PFIZER INC 2003-12-16 US disclosed
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds PFIZER INC. 2003-04-24 US disclosed
EP-1247810-A1 Novel benzotriazoles anti-inflammatory compounds Pfizer Products Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds MAPK1, JAK1, RUNX1 MAPK14 27/4885MAPK13 48/4885MAPK12 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.